Pure Extracts: Recurring Revenue with Blue Sky Potential



Ryan Allway

November 17th, 2020

App, Exclusive, News, Top Story


The global cannabis extract market is projected to reach $28.5 billion by 2027, according to Grand View Research, representing a 16.6% compound annual growth rate. In addition to the relatively mature cannabis market, the wider market for plant-based extracts could see tremendous growth from the functional mushroom revolution.

Let’s take a look at how Pure Extracts Technologies Corp.’s (CSE: PULL) unique combination of recurring revenue and blue sky potential has opened the door for investors.

Recurring Tolling Revenue

Pure Extracts operates a 10,000 sq. ft. state-of-the-art EU-GMP-compliant cannabis and hemp extraction facility with a Health Canada Standard Processing License. With existing contracts secured with licensed producers, the Company is already generating revenue through tolling and white label agreements where it converts biomass into higher value extracts.

CEO Ben Nikolaevsky discusses the breakdown of Pure Extracts extraction business model

  • Tolling takes biomass from licensed producers, runs an extraction process and returns the cannabis oil to the LP for a fee to put into their own products or resell.
  • White-labeling takes biomass from licensed producers, runs an extraction process and produces a range of products, such as vapes or tinctures, that LPs can sell.

Over the coming quarters, the Company plans to expand its production capacity to process upwards of 100,000 kilograms per year. The Company also plans to apply for a Natural Health Products Site License for the extraction of mushroom compounds and apply for EU-GMP certification of its operations to eventually export products to Europe.

Click here to receive and investor presentation and corporate updates

Blue Sky Branding Potential

Pure Extracts has developed a nationally-recognized vape pen brand called Pure Pulls with over 34 proprietary formulations. While the Company’s vape brand is well known, the Company also plans to launch tinctures, soft gel capsules and other products on both a branded and private label basis across the country.

CEO Ben Nikolaevsky discusses Pure Extracts’ value proposition

In addition to launching its own products, the Company has continued to double down on its investment in research and development. Dr. Alexander MacGregor, a leading Canadian scientist and founder of the Toronto Institute of Pharmaceutical Technology (TIPT), recently joined the Company in an advisory role to advance its research and development.

Dr. MacGregor has a narcotics license that opens the door to research into psilocybin production. As the Canadian medical community adopts psilocybin, the Company aims to leverage its functional mushroom experience to apply for a Dealer’s License and eventually become a leading supplier of pharmaceutical grade mushroom extracts into the medical space.

Click here to receive and investor presentation and corporate updates

Looking Ahead

Pure Extracts Technologies Corp. (CSE: PULL) is well positioned for rapid growth in the plant-based extract sector with 34 proprietary formulations and plans to expand into functional mushrooms. In addition to its commercial ambitions, the Company also continues to invest in research and development initiatives under the guidance of its new advisor, Dr. Alexander MacGregor.

Investors may want to take a closer look at the newly public company due to its unique combination of processing agreements and blue sky potential. With established sources of recurring revenue, Pure Extracts has access to the cash flow that it needs to invest in its own products and research that will have even greater long-term potential.

For more information, visit the Company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Latest posts